SCHEMBL265251

SCHEMBL265251

CCCC(=O)N(CC(=O)O)CC(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR3 O14843 1/20 0.50
HDAC3 O15379 1/20 0.50
HDAC1 Q13547 1/20 0.50
HDAC2 Q92769 1/20 0.50
HDAC8 Q9BY41 1/20 0.50
LMNA P02545 1/20 0.42
ALDH1A1 P00352 3/20 0.40
HPGD P15428 1/20 0.40
TP53 P04637 1/20 0.39
CES2 O00748 1/20 0.39
CES1 P23141 1/20 0.39
AKR1B1 P15121 1/20 0.39
GPR84 Q9NQS5 7/20 0.37
PPARG P37231 6/20 0.37
PPARD Q03181 6/20 0.37
PPARA Q07869 6/20 0.37
HDAC11 Q96DB2 5/20 0.37
TSHR P16473 4/20 0.37
TLR2 O60603 2/20 0.37
TDP1 Q9NUW8 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24331732 0.91 FFAR3 (0.42) FFAR3HDAC3HDAC1HDAC2HDAC8
SCHEMBL6138052 0.91 LMNA (0.50) FFAR3HDAC3HDAC1HDAC2HDAC8
SCHEMBL9726150 0.86 FFAR3 (0.38) FFAR3HDAC3HDAC1HDAC2HDAC8
SCHEMBL28613948 0.85 MMP1 (0.47) FFAR3HDAC3HDAC1HDAC2HDAC8
SCHEMBL10950026 0.84 AKR1B1 (0.56) LMNAALDH1A1AKR1B1GPR84PPARG
SCHEMBL14435161 0.82 GPR84 (0.58) ALDH1A1AKR1B1GPR84PPARGPPARD
SCHEMBL1115961 0.82 GPR84 (0.58) ALDH1A1AKR1B1GPR84PPARGPPARD
Ammonia Solution, Strong SCHEMBL11417642 0.81 GPR84 (0.56) ALDH1A1AKR1B1GPR84PPARGPPARD
Ammonia Solution, Strong SCHEMBL11436995 0.81 GPR84 (0.56) ALDH1A1AKR1B1GPR84PPARGPPARD
SCHEMBL3470710 0.81 GPR84 (0.56) ALDH1A1AKR1B1GPR84PPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11767294-B2 Conjugates of cell binding molecules with cytotoxic agents HANGZHOU DAC BIOTECH CO., LTD. (CN) 2023-09-26 US disclosed
WO-2023078273-A1 SPECIFIC CONJUGATION FOR AN ANTIBODY-DRUG CONJUGATE HANGZHOU DAC BIOTECH CO., LTD. (CN) 2023-05-11 WO disclosed
US-9988408-B2 Cytotoxic agents for conjugation to a cell binding molecule HANGZHOU DAC BIOTECH CO., LTD. (CN) 2018-06-05 US disclosed
US-20160207949-A1 NOVEL CYTOTOXIC AGENTS FOR CONJUGATION TO A CELL BINDING MOLECULE HANGZHOU DAC BIOTECH CO., LTD (CN) 2016-07-21 US disclosed
US-8629126-B2 Quinolone derivative or pharmaceutically acceptable salt thereof ASTELLAS PHARMA INC. (JP) 2014-01-14 US disclosed
US-8629126-B2 Quinolone derivative or pharmaceutically acceptable salt thereof ASTELLAS PHARMA INC. (JP) 2014-01-14 US disclosed
US-20120165275-A1 Nitrogen-Based Linkers for Attaching Modifying Groups to Polypeptides and Other Macromolecules AFFYMAX, INC. (US) 2012-06-28 US disclosed
US-20120136025-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ASTELLAS PHARMA INC. (JP) 2012-05-31 US disclosed
US-20120136025-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ASTELLAS PHARMA INC. (JP) 2012-05-31 US disclosed
US-8133882-B2 Quinolone derivative or pharmaceutically acceptable salt thereof ASTELLAS PHARMA INC (JP) 2012-03-13 US disclosed
US-8133882-B2 Quinolone derivative or pharmaceutically acceptable salt thereof ASTELLAS PHARMA INC (JP) 2012-03-13 US disclosed
EP-1995240-B1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ASTELLAS PHARMA INC (JP) 2012-02-22 EP disclosed
US-20090197834-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ASTELLAS PHARMA INC. (JP) 2009-08-06 US disclosed
US-20090197834-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ASTELLAS PHARMA INC. (JP) 2009-08-06 US disclosed
EP-1995240-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Astellas Pharma Inc. (JP) 2008-11-26 EP disclosed
US-20080090760-A2 Compositions and Methods for Inhibiting Cellular Proliferation HEMBROUGH TODD 2008-04-17 US disclosed
US-20080090760-A2 Compositions and Methods for Inhibiting Cellular Proliferation HEMBROUGH TODD 2008-04-17 US disclosed
US-20070203066-A1 Compositions and methods for inhibiting cellular proliferation ENTREMED, INC. 2007-08-30 US disclosed
US-20070203066-A1 Compositions and methods for inhibiting cellular proliferation ENTREMED, INC. 2007-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165275-A1 Nitrogen-Based Linkers for Attaching Modifying Groups to Polypeptides and Other Macromolecules DNPEP, NGLY1, LNPEP FFAR3 4176/4885HDAC3 3544/4885HDAC1 3080/4885
US-20120136025-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF P2RY10, P2RY12, P2RY11 FFAR3 394/4885HDAC3 1789/4885HDAC1 4298/4885
US-20160207949-A1 NOVEL CYTOTOXIC AGENTS FOR CONJUGATION TO A CELL BINDING MOLECULE PDCD5, CD4, PDCD6 FFAR3 3486/4885HDAC3 2221/4885HDAC1 2251/4885
US-11767294-B2 Conjugates of cell binding molecules with cytotoxic agents CD4, CD2, CD47 FFAR3 1181/4885HDAC3 3244/4885HDAC1 2289/4885
US-20080090760-A2 Compositions and Methods for Inhibiting Cellular Proliferation MKI67, VEGFA, HDGF FFAR3 4297/4885HDAC3 3156/4885HDAC1 1489/4885
US-20090197834-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF P2RY12, P2RY11, P2RY10 FFAR3 401/4885HDAC3 2406/4885HDAC1 4515/4885
US-20070203066-A1 Compositions and methods for inhibiting cellular proliferation MKI67, VEGFA, HDGF FFAR3 4297/4885HDAC3 3156/4885HDAC1 1489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.